

Supplementary Materials

Table S1. Univariate and multivariable analyses of local progression-free survival

Variable	Univariate analysis		Multivariate analysis	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Sex (male vs. female)	1.90 (0.72–5.04)	0.20		
Age (≥ 65 vs. < 65 yr)	1.22 (0.48–3.10)	0.68		
KPS (90–100 vs. 70–80)	0.75 (0.17–3.29)	0.71		
Disease extent (BRPC vs. LAPC)	0.98 (0.39–2.47)	0.97		
Tumor location (head vs. other)	1.67 (0.66–4.24)	0.28		
Tumor size (≥ 3.6 vs. < 3.6 cm)	0.63 (0.26–1.57)	0.32		
Baseline CA19-9 (> 148 vs. ≤ 148 U/mL)	3.93 (0.79–19.53)	0.095		
Chemo duration (> 4 vs. ≤ 4 mo)	1.01 (0.39–2.57)	0.99		
PNI (absent vs. present)	0.53 (0.18–1.60)	0.26		
LVI (absent vs. present)	0.49 (0.20–1.25)	0.14		
Adjuvant/maintenance chemotherapy (yes vs. no)	0.41 (0.14–1.21)	0.11		
<i>KRAS</i> (mutant vs. wild type)	23.30 (0.019–28,351.67)	0.39		
<i>TP53</i> (mutant vs. wild type)	0.79 (0.32–1.95)	0.61		
<i>NOTCH1/2</i> (mutant vs. wild type)	1.87 (0.65–5.33)	0.24		
<i>CDKN2A</i> (mutant vs. wild type)	0.99 (0.33–2.99)	0.99		

KPS, Karnofsky Performance Score; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; CA19-9, cancer antigen 19-9; PNI, perineural invasion; LVI, lymphovascular invasion; HR, hazard ratio; CI, confidence interval.